Previous Close | 8.05 |
Open | 8.16 |
Bid | 6.50 x 900 |
Ask | 8.21 x 900 |
Day's Range | 7.86 - 8.16 |
52 Week Range | 3.96 - 28.67 |
Volume | |
Avg. Volume | 366,127 |
Market Cap | 476.81M |
Beta (5Y Monthly) | 1.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.27 |
Earnings Date | Aug 04, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.50 |
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cash balance of $312.2M expected to fund operations into 2025CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progre
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be avai